Cancer Family
Nervous System Neoplasm
CI-CAN-00000038Explore in graph →
Non-malignant1,523 active trials9 approved drugs210 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000038Explore in graph →
Clinical trials
5,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06492486 | Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow(GLADIATOR) | recruiting | Phase 2 | 60 | Tata Memorial CentreOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07243340 | A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor | recruiting | Phase 1 / Phase 2 | 36 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Aug 17, 2026 | clinicaltrials |
| NCT07440290 | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04774718 | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors | active not recruiting | Phase 1 / Phase 2 | 42 | Hoffmann-La RocheINDUSTRY | 11 | Aug 14, 2026 | clinicaltrials |
| NCT06812871 | High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis | completed | Phase 2 | 46 | Sun Yat-sen UniversityOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT01326104 | Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor(Re-MATCH) | completed | Phase 2 | 26 | University of FloridaOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT07150806 | RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma | recruiting | Phase 1 / Phase 2 | 30 | Joshua PalmerOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT04696029 | DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma | recruiting | Phase 2 | 118 | Giselle ShollerOTHER | 2 | Aug 12, 2026 | clinicaltrials |
| NCT05489887 | Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma | recruiting | Phase 2 | 93 | Giselle ShollerOTHER | 4 | Aug 12, 2026 | clinicaltrials |
| NCT06161519 | PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications | recruiting | Phase 1 / Phase 2 | 146 | National Cancer Institute (NCI)NIH | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06777433 | Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases(RAD101) | active not recruiting | Phase 2 | 30 | Radiopharm Theranostics, LtdINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07527169 | A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma | not yet recruiting | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT04936529 | A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma | recruiting | Phase 2 | 286 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT05642455 | SPEARHEAD-3 Pediatric Study | recruiting | Phase 1 / Phase 2 | 20 | USWM CT, LLCINDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06666348 | Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK(MIRV) | recruiting | Phase 1 / Phase 2 | 50 | St. Justine's HospitalOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07549022 | Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor | recruiting | Phase 1 / Phase 2 | 17 | Ankit Mangla, MDOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07758062 | Levetiracetam Extended-Release Plus Stupp Protocol for Hypoxic IDH-Wildtype Glioblastoma(ELITE) | not yet recruiting | Phase 2 | 140 | Tianjin Medical University General HospitalOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04469075 | Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields | active not recruiting | Phase 2 | 48 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07383649 | Trial to Study Anti- HCMV Therapy in Breast Cancer Patients With Progressive Intracranial Metastases and CMV Infection | recruiting | Phase 2 | 28 | The Methodist Hospital Research InstituteOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07501559 | A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of JL15003 Injection in Patients With Recurrent Glioblastoma (rGBM) | recruiting | Phase 1 / Phase 2 | 40 | Jecho Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07754734 | STUPP Regimen With or Without Lenvatinib for Newly Diagnosed Glioblastoma With MGMT Promoter Methylation | not yet recruiting | Phase 2 | 138 | Dongguan People's HospitalOTHER_GOV | 0 | Aug 10, 2026 | clinicaltrials |
| NCT02455557 | SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 2 | 66 | Roswell Park Cancer InstituteOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07751744 | Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma | not yet recruiting | Phase 1 / Phase 2 | 113 | Jubilant Therapeutics Inc.INDUSTRY | 0 | Aug 7, 2026 | clinicaltrials |
| NCT01837862 | A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | active not recruiting | Phase 1 / Phase 2 | 10 | Julie KrystalOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT01891318 | Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study | recruiting | Phase 1 / Phase 2 | 36 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT03862430 | A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM(RESTORE) | active not recruiting | Phase 2 | 87 | NuvOx LLCINDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07003542 | A Phase 2 and Pharmacodynamic Study of Sitagliptin in Patients With Progressive Grade 4 Gliomas | recruiting | Phase 2 | 48 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07749365 | Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCL | recruiting | Phase 2 | 53 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT00911560 | Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma | completed | Phase 1 / Phase 2 | 374 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT04906096 | Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL | recruiting | Phase 2 | 25 | Lakshmi Nayak, MDOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05235074 | OH2 Oncolytic Viral Therapy in Central Nervous System Tumors | completed | Phase 1 / Phase 2 | 40 | Binhui Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05708352 | A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment | recruiting | Phase 2 | 170 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06940791 | Tirabrutinib Maintenance Versus Placebo in Patients With Primary CNS Lymphoma in Complete Remission (JCOG2104)(TIMELY-pII) | recruiting | Phase 2 | 92 | Kyorin UniversityOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT03643549 | Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17)(BORTEM-17) | recruiting | Phase 1 / Phase 2 | 63 | Haukeland University HospitalOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07680439 | Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG). | recruiting | Phase 2 | 75 | BrainChild Bio, IncINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07743554 | Combination of Avutometinib and Defactinib for Treatment of Relapsed, Refractory, Metastatic, or Unresectable Malignant Peripheral Nerve Sheath Tumor(NF120) | not yet recruiting | Phase 2 | 23 | Girish Dhall, MDOTHER | 0 | Aug 4, 2026 | clinicaltrials |
| NCT03868943 | Solriamfetol in Improving Sleep in Patients With Grade II-IV Glioma(JAZZ) | terminated | Phase 2 | 2 | Wake Forest University Health SciencesOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT04320888 | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial | active not recruiting | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 3 | Aug 3, 2026 | clinicaltrials |
| NCT06239272 | NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | recruiting | Phase 1 / Phase 2 | 139 | St. Jude Children's Research HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT02152982 | Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | active not recruiting | Phase 2 / Phase 3 | 447 | National Cancer Institute (NCI)NIH | 2 | Jul 31, 2026 | clinicaltrials |
| NCT03604978 | Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma | active not recruiting | Phase 1 / Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06069726 | A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial(MOAB) | recruiting | Phase 2 | 80 | Duke UniversityOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07206849 | Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG) | not yet recruiting | Phase 2 | 79 | Nationwide Children's HospitalOTHER | 0 | Jul 31, 2026 | clinicaltrials |
| NCT07402343 | Tarlatamab for SCLC Brain Metastases(T-BRAIN) | recruiting | Phase 2 | 35 | Maastricht University Medical CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03363373 | Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow | active not recruiting | Phase 2 | 122 | Y-mAbs TherapeuticsINDUSTRY | 9 | Jul 30, 2026 | clinicaltrials |
| NCT03970447 | A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma(GBM AGILE) | recruiting | Phase 2 / Phase 3 | 2,250 | Global Coalition for Adaptive ResearchOTHER | 6 | Jul 30, 2026 | clinicaltrials |
| NCT05781321 | Short Course Radiotherapy for the Treatment of Patients With Glioblastoma, SAGA Study | active not recruiting | Phase 2 | 170 | Mayo ClinicOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT06991101 | Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma | recruiting | Phase 2 | 190 | Baptist Health South FloridaOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07533942 | A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma | recruiting | Phase 2 | 30 | Jazz PharmaceuticalsINDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Aug 17, 2026source: clinicaltrials